GE HealthCare 10-Q Backs Up Q3 Beat; Discloses $945M SOFIE Deal and New Iraq Lawsuit
GEHC sits 27% above its 52-week low of $58.75.
Summary
GE HealthCare's Q3 10-Q confirms the morning's beat — revenue of $5,513 million, up 7.2%, and adjusted EPS of $1.34 — while disclosing a $945 million cash acquisition of SOFIE Biosciences, a new Iraq terrorism lawsuit, and an unaccrued IRS indemnity exposure.
Key Events · Earnings and Guidance · GEHC
-
Q3 Beat Confirmed in Full 10-Q
Revenue of $5,513 million rose 7.2% (6.2% organic) and adjusted EPS of $1.34 grew 25.1%; adjusted EBIT margin expanded 180 bps to 16.6%.
-
$945M SOFIE Acquisition Disclosed
Announced October 5, 2026, the all-cash purchase of PET radiopharmaceutical contract manufacturer SOFIE Biosciences is expected to close in the first half of 2027, subject to regulatory approvals.
-
Cash Down on Intelerad Purchase
Cash, cash equivalents and restricted cash fell to $2,854 million from $4,512 million at December 31, 2025, primarily on the $2,293 million Intelerad acquisition; nine-month free cash flow was $973 million versus $589 million.
-
New Iraq Terrorism Lawsuit Filed
A similar group of plaintiffs filed a substantially similar Anti-Terrorism Act complaint in September 2026; defendants sought Supreme Court review in August 2026 and no loss estimate is possible.
Analysis · GEHC · Industrial Applications And Services
The headline numbers were already out this morning, but the full 10-Q adds the balance sheet and three items investors did not have: a $945 million cash deal for SOFIE Biosciences that extends the radiopharmaceuticals build-out, a new Anti-Terrorism Act complaint filed in September 2026, and an IRS audit of 2016-2020 GE consolidated returns that could create material indemnification obligations to GE with no liability accrued. Cash fell to $2,854 million from $4,512 million at year-end, largely on the $2,293 million Intelerad purchase, but nine-month free cash flow of $973 million was up 65.2% and the $3,500 million of revolver capacity is undrawn. The quarter itself was strong: revenue of $5,513 million rose 7.2% and adjusted EPS of $1.34 rose 25.1%, with adjusted EBIT margin up 180 bps to 16.6%.
How filings like this one have moved
In the 30 days to Oct 28, 2026, 36.5% of the 953 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.66%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GEHC was trading at $74.90 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $32.1B. The 52-week trading range was $58.75 to $89.77. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.